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Abstract
Significant public health issues caused by adverse drug reactions in the post-marketing 
phase, such as birth defects by thalidomide, have been well described. Unfortunately, 
subjects in clinical trials cannot completely avoid severe harm during drug development. 
TGN1412 in 2006 and BIA 10-2474 in 2016 were withdrawn from development due to 
severe adverse reactions in first-into-man studies. Thus, monitoring drug safety is impor-
tant throughout all phases of development. In twenty-first century, minimizing drug 
development cost and time is a challenge for pharmaceutical companies. When a drug is 
approved with a smaller size and fewer number of clinical trials, pharmacovigilance and 
benefit-risk evaluation after marketing need to be sufficiently performed. Underpinned 
by understanding of the traditional methods of evaluating adverse drug reactions, new 
developments in IT and computing might well help us to detect drug safety signals ear-
lier, enabling prompt intervention for protecting the rights of subjects and public health.
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1. Introduction
A new drug application dossier, accompanied with the Common Technical Document (CTD), 
needs to provide a risk management plan, and a marketing authorization holder needs to set 
up both the policy framework and a quality system for pharmacovigilance. This approach 
has become more important and valuable in regulating drugs, because the novelty, rarity, 
or technical specificity of drugs produces complexities to evaluating efficacy and safety. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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Furthermore, in this decade, the risk-based approach for application has been proposed to 
address and evaluate potential risks associated with the clinical use of medicines, with regard 
to quality, safety, and efficacy. While the risk-based approach is to be differentiated from the 
risk management system or the benefit-risk assessment for evaluating marketing authoriza-
tion, the idea is very close to it. This chapter introduces pharmacovigilance in the clinical 
development phase, especially with the aim of stimulating discussion about identification of 
risks associated with the clinical use of drugs qualitatively and quantitatively.
1.1. What to do when any clinical safety problem happen in the development 
phase?
Throughout the history, humans have used a variety of different therapies to treat injuries 
and diseases. During the nineteenth century, medicines were developed by separating, iso-
lating, and extracting certain active ingredients from medicinal plants, e.g., morphine, qui-
nine, and ephedrine. Then, in twentieth century, chemists discovered new chemicals, e.g., 
penicillin and streptomycin, from bacteria and synthesized better chemical substances of 
sulfonamides. In the first decades of twenty-first century, the development of drugs had 
been dramatically changed. Pharmaceuticals benefit from advances in all fields relating to 
medicine, e.g. pharmacology, physiology, and biochemistry, and were derived from synthetic 
compounds to target a certain site of action. For example, the progresses in medical science 
helped to reveal many of the mechanisms of the pathophysiological and pharmacological 
effects at the molecular level; for example, cimetidine and histamine-2 receptor blocker, which 
was a break through pharmacotherapy at that time for gastric ulcer. Molecular-targeted drugs 
now have been developed to treat various diseases, especially targeting specifically expressed 
molecules of cancer cells, e.g., imatinib.
Common to all pharmaceuticals is that they can bring both benefits and risks to humans. 
Thalidomide, which is now administered with dexamethasone to multiple myeloma patients, 
used to be first sold in West Germany as a sedative or hypnotic drug in 1950s, and then it was 
withdrawn from the market in 1961, because it was found to be responsible for teratogenic 
deformities in children based on reports of children of those mothers who took thalidomide 
during pregnancy. This tragedy was both a pre- and post-marketing landmark; countries 
recognized the need of adequate testing of medicines prior to marketing, the regulation of 
medicines, and the systems to identify the adverse effects of medicines as well as the poten-
tial relationship between marketing claims and safety [1, 2]. Because of the need for effective 
therapies in myeloma, thalidomide demonstrated sufficient benefit to achieve authorization 
and turned around the balance of benefit-risk from negative evaluation. This depended on 
effective risk minimization to prevent pregnancies in those who receive thalidomide.
International activities actively promoted regulations and empirical knowledge on clinical 
development in 1990s. However, in twenty-first century, one programme of an investigational 
medicinal product was withdrawn due to serious adverse reactions in the first-in-human clin-
ical trial in 2006. This was known as TGN1412, a CD28 superagonist monoclonal antibody. Six 
volunteers were seriously afflicted by a cytokine-release syndrome requiring intensive care 
just after they received a bolus injection of TGN1412.
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Although many new drugs implement a lifecycle risk management, another tragedy in clin-
ical trial happened with a dose-finding study for BIA 10-2474, an experimental fatty acid 
amide hydrolase inhibitor for the treatment of anxiety disorder, Parkinson’s disease, etc. An 
acute and rapid progressive neurologic syndrome developed on the fifth day of BIA 10-2474 
administration (50 mg). The underlying mechanism of adverse drug reaction is still unknown 
regarding BIA 10-274, but it is supposed to be associated with drug accumulation as no clini-
cal severe adverse events had been observed in single dose (0.25–100 mg) and 10-day admin-
istration (0.25–20 mg) [3].
The stories addressed above are extreme examples. However, a number of drug develop-
ment programmes have been abandoned because of safety concerns or lack of efficacy. As 
mentioned in ICH Good Clinical Practice (GCP) [4], “A trial should be initiated and continued 
only if the anticipated benefit justifies the risks.” Thus, sponsors need to make sure that ben-
efit for patients should overweigh risk to patients. Information sharing and a system for risk 
management throughout the lifecycle of drugs from preclinical, clinical, and post-marketing 
are crucial, and this is reflected in the development safety update report (DSUR) which had 
been proposed [5] and then taken forward by the International Conference on Harmonization 
of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) [6]. This 
emphasizes the importance of the principle of the benefit-risk balance, which is supported by 
pharmacovigilance concepts which originally emerged in the post-marketing phase.
1.2. The latest strategy to promote marketing a new medicine
Drugs are approved based on the evidence of efficacy and acceptable level of harm that 
have been observed during clinical trials. Now, to tackle remaining unmet needs of patients 
globally, the regulatory schemes for supporting early access have been adopted, such as 
compassionate use, accelerated assessment by regulatory agencies, and conditional market-
ing authorization. If it is expected to have new medicines with conditional use, an appli-
cant is allowed to provide comprehensive data after approval. Once such a new medicine 
is approved, definitely, there is little evidence of efficacy and safety in real-world practice, 
so that effective pharmacovigilance should produce the important data to supplement the 
evidence as well as cost savings for an applicant in the drug development. As we receive 
more applications of early access program, the more careful that we should be to pay atten-
tion with not to confusing “absence of evidence” with “evidence of absence” at approval. It is 
critical to detect precisely and promptly the harms potentially caused by an investigated drug 
(monitoring), to assess individual cases (qualitative evaluation) and comparative groups as 
planned (quantitative evaluation), and to finalize benefit-risk assessment at defined points in 
time (Figure 1).
How we can define “risk” then? According to the International Organization for Standardiza-
tion, risk is the “effect of uncertainty on objectives” [7] and in terms of drug development, the 
objectives are patients’ and public health. Another definition can be “combination of the prob-
ability of occurrence of harm and the severity of that harm” for medical devices and manu-
facturing medicinal products [8, 9]. As such, risks related to use of a drug is defined “any risk 
relating to the quality, safety or efficacy of the medicinal product as regards patients’ health 
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or public health and any risk of undesirable effects on the environment” [10]. In traditional 
pharmacovigilance, the concept of risk concerns adverse drug reactions [11], as described later, 
however EU regulations now emphasize that it is as been expanded to include ineffective use 
outside the label, misuse and abuse. In reality for pharmacovigilance, we propose to bear in 
mind other systematic factors impacting risks of medicines as well (such as facilities, proce-
dures, computerized systems) that may cause medication errors. Those risks cannot be evalu-
ated enough in drug development, therefore the plan is necessary to continue vigilance once 
marketed and take action once a potential harm is identified. Thus pharmacovigilance has 
become even more important to manage various safety problems with these new rapid access 
regulatory approvals.
Risk management encompasses “risk assessment” and “risk minimization” with the man-
agement cycle to assess, implement, evaluate, and modify safety measures; the former is to 
identify and characterize the nature, frequency, and severity of the risks associated with the 
use of a product, as focused in this chapter; the latter is to minimize or mitigate a product’s 
risks through communication, education, and restriction of use while preserving its benefit.
2. Pharmacovigilance in clinical trials
Data obtained from clinical trials vary depending on the situation of an investigational sub-
stance and those are different from post-marketing data; the patient being administered can 
be perfectly observed, the number of patients is small, and the information on subjects can be 
Figure 1. Drug development process and clinical data review. The figure is arranged and restructured from some of 
slides provided with the kind permission of the Product Safety Culture Initiative in the Alliance for Clinical Research 
Excellence and Safety.
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biased under restrictions of subjects’ health background. As with post-marketing data collec-
tion, the data collection method is an essential element of the pharmacovigilance process dur-
ing clinical trial with proper data collection to enable analysis of medical interpretation of the 
case narrative and the aggregated data. Evaluation of case information obtained in clinical trials 
is possible by use of the approaches cultivated in pharmacovigilance over years of experience.
2.1. Characteristics of pharmacovigilance in clinical trials
It is commonly known that not all hazards can be found before a drug is marketed. Phar-
macovigilance is the science and activities relating to the detection, assessment, understand-
ing and prevention of adverse effects or any other possible drug-related problems [12]. It is 
now also more involved in pre-approval drug assessment as well-designated clinical trials 
in phase IV, referred to “the clinical safety activities throughout the lifecycle of a medicinal 
product” [13]. Drugs at approval have limited clinical information from clinical trials. For 
example, 16,000 subjects are needed to receive a drug to detect one adverse drug event out of 
10,000 people with 80% probability, while clinical trials for most new drugs are conducted 
with 2000–3000 patients prior to approval. Therefore, rare adverse drug reactions are hardly 
detected, although relatively common adverse drug reactions (ADRs) are identified. Patients 
with complex conditions are excluded in order to eliminate factors that may affect efficacy 
of a tested drug. Most, but not all, ADRs occur in rather short time after administration. The 
short duration of observation, for example, 1 year or less in clinical trials is another limita-
tion that will not observe late-onset ADRs. CIOMS VI [13] would help readers understand 
systematic approach for safety management during clinical development. Missing informa-
tion at approval concerning clinical safety often refers to use in children, elderly, kidney 
disorders, drugs for oncology, HIV, vaccines, biologicals, and other advanced drugs as they 
will all mostly have a comparatively small number of subjects. All those limitations are to 
be addressed in pharmacovigilance plan for post-marketing. Clinical trials need to be moni-
tored by the Data and Safety Monitoring Boards (DSMBs), also known as Data Monitoring 
Committees (DMC), who periodically review and evaluate the accumulated data from one 
or multiple clinical trials for safety of trial subjects. After DSMB evaluation, apparently obvi-
ous favorable or unfavorable results in the treatment group will lead to recommendations 
to discontinue a trial for the reason of negative benefit-risk in the treatment of the control 
group. However, the benefit-risk assessment continues throughout the drug development 
lifecycle.
2.2. Hazard data collection: planning and practical realization
Although there are regulatory systems for both pre- and post-marketing individual case 
safety reports (ICSRs), the concept of cases to be reported is somewhat different between pre 
and post. After marketing, it is rather appropriate to pay more attention to unknown serious 
adverse reactions than known or non-serious ADRs, although the latter can provide useful 
supporting information about risk factors and nature of known ADRs. Clinical trials explore 
unknown properties and use of a medicine, and so taking ethics into account, all adverse 
events (AEs) must be collected and in addition, serious and unexpected adverse events are 
subject to expedited reporting.
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All serious adverse events must be assessed regardless of causality by the applicant at the 
time of application submission. Furthermore, what kind of AE data can be collected in the 
development phase depends on the clinical evaluation stage in the development process in 
which the investigational drug is as described in the protocol. The judgment as to whether a 
case is expected (known) or unexpected (unknown) is based on the labeling of the marketed 
drug, while in clinical trials, the reference safety information in the investigator’s brochure 
is used. It is necessary for clinical trial sponsors to update the investigator’s brochure at any 
time as needed, and the latest reference safety information receives close regulatory attention 
to ensure it is up to date for the judgment of known/unknown (or listed/unlisted) cases.
In addition, since many of post-marketing ICSRs are spontaneous reports, there is a vast 
range in the quality of the information from rich cases to poor cases (e.g., age/gender, drug, 
and adverse event are minimum requirements for regulatory reporting), mostly without labo-
ratory results and the exact size of the exposed population is unknown. Since laboratory test 
values of participants in a clinical trial are regularly collected, assessment of individual case 
safe report, described later in this chapter, should effectively utilize theses results for each 
subject as well as the corresponding case narratives. Clinical trials have detailed information 
on cases such as the AE development date and dose (details of which are often missing in 
post-marketing ICSRs) and the size of population is known, so it is possible to calculate the 
frequency of occurrence and the incidence of AE. Of course, efficacy is statistically evaluated 
in a prospective statistical analysis plan. Various designs of clinical investigation are avail-
able, not only clinical trials for the development of new drugs but also that for the extension 
of indication of existing drugs, development of new routes of administration, and changes in 
dosage regimen.
As regard to data collection of safety information in clinical trials, the Good Clinical Practice 
guideline [6] does not address details of standards for the types of data to be collected for 
safety monitoring although traditionally reliance has been placed mainly on AE case reporting 
to the regulatory agencies. While another guideline, ICH E2A [14], specify only the key data 
elements for inclusion in expedited reports of serious unexpected adverse drug reactions, it is 
prudent to collect more comprehensive safety data during development because poorly estab-
lished safety profiles need to be clarified in greater detail with the collection of non-serious 
adverse events and essential laboratory data. Therefore, the study protocols should be well 
designed defining the data to be collected, which differs according to characteristics of a drug.
When collecting data, sponsors may prepare different procedures for targeted or untargeted 
AE detection. However, the methods are commonly used in the same manner such as ques-
tionnaires, patient diary cards, and medical records supplemented with serious adverse event 
(SAE) reporting forms. Safety outcomes can be presented using descriptive text or visual ana-
logue scales for severity rating, based on subjective opinion, of adverse events during inves-
tigation, pre-, during-, and post-trial, since a participant was enrolled. Patients’ opinions may 
not be scientifically presented, but an understanding of benefit and risk and impact of an AE 
on quality of life, thereby revitalizing patient-focused drug development, can be elaborated. 
Narratives are important information for in-depth investigation of suspected unexpected seri-
ous adverse drug reactions (SUSARs) and to understand the reasons why a participant has 
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dropped out from a trial. A protocol needs to specify testing intervals and thresholds for 
evaluating data later. Discordance of coding interpreted from collected data will cause both 
false positives and false negatives. Issues of coding, if left unresolved, will worsen with mul-
ticenter research which will provide aggregate data for quantitative analysis.
How data are presented influences the impression that an assessor would have. An appropri-
ate approach should be selected among many options such as tables with strata according 
to, for example, dosage, duration of treatment with scatter plots for clinical chemical data, 
Kaplan-Meier plots for cumulative hazard clinical chemical data and outcome evaluation, 
and so on.
2.3. Safety profile and risk assessment
It is important to gain an understanding of the safety profile of a drug as early and as much 
as possible during development as possible as risks can be more easily controlled. Once the 
efficacy is proven at the end of clinical development, the benefit-risk profile of the drug is 
reviewed whether it is acceptable for approval. Both medical judgment (qualitative) and sta-
tistics including descriptive and inferential approach (quantitative) influence the evaluation 
of clinical safety during drug development. The same principles apply to post-marketing 
evaluation. It is more likely, however, that safety signal detection and assessment during 
clinical development depend as much on clinical judgment with case reports, especially for 
serious rare AEs. Such an approach is reasonable and necessary for small-size trials, since data 
accumulation is limited due to the small number of subjects. With accumulated data, statisti-
cal methods are possibly available for the evaluation of safety signals in clinical trials, espe-
cially for more commonly occurring adverse events, and it is certainly a practical option to 
use a database for the phase IV studies especially after conditional approval has been granted. 
Any approaches need to consider patient population characteristics including natural history 
of disease and current therapeutic standards for comparison, when evaluating safety. Safety 
evaluation is the basis of risk assessment as a whole, and it is required to report an unusual 
or worrying ICSR, especially for AE of special interest, routinely anytime and when a certain 
evaluation milestone is reached such as with DSUR submissions.
Risk assessment as a part of pharmacovigilance in drug development requires analyzing and 
interpreting the safety profile. After risk assessment, investigator’s brochure may be updated 
and risk management measures may be taken to minimize the risks, if necessary and medi-
cally significant. From perspectives of public health, risk assessment and decision-making 
should be done at the right time rather to wait for punctual dataset for review.
Although the clinical efficacy is steadily and iteratively demonstrated through phase I, II, 
and III, and then confirmed at the end of development, serious harm can occur at any stage 
of drug development. Thus pharmacovigilance in drug development may be more of a risk-
based approach relating to any other drug-related issues that could affect patient safety and 
safe use of drug, including concerns about quality and efficacy as well as safety. In this sense, 
pharmacovigilance is consistent with a “risk-based approach” which to some extent can be 
found in regulatory guidances recently [15–17].
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3. What can be done for “evaluating benefit-risk balance”?
Many methods have been proposed and each of them gives us thoughts to some extent. So, 
do we need to apply all to our daily work? Those evaluation methods have been reviewed 
in terms of usefulness in benefit-risk assessment and reported by the European Medicines 
Agency, suggesting three quantitative methods for regulatory assessment use, Bayesian sta-
tistics, Decision trees and influence/relevance diagrams and Multi-criteria analyses, as well 
as qualitative approach [18]. They also pointed out some limitations, for example, Bayesian 
statistical model do not generally deal with multiple criteria, and some other approaches 
such as conjoint analysis may contribute to some specific cases. An assessment process, which 
includes many dimensions of public health to consider, will be enforced by the integration 
of methods/approaches. Authors make the point that quantitative methods/approaches are 
effectively adopted in practice only when a qualitative approach works.
3.1. Basic processes of adverse event evaluation
The identification of a potential safety issue for a drug requires processes to distinguish adverse 
reactions from unrelated adverse events. These cases can be found in reports submitted to regu-
latory authorities or published articles/posts through journals, media and even through social 
media and Internet. As a basic reference for risk assessment, the evaluation result of each indi-
vidual case of suspected ADRs, as well as adverse events, is important because even one ADR 
case can be sufficient by evidence itself of a risk serious enough to stop a clinical trial. Therefore, 
the first step of the process is the assessment of individual case observations, and the difficulties 
of causality assessment are addressed further in the next Section 3.2. Case evaluation needs to 
consider clinical significance, seriousness, severity (continuous variables), and expectedness 
based on the latest investigator’s brochure, causality, place and time of occurrence, dosage, 
and predisposing factors of trial subject. AEs based on laboratory data need to be interpreted 
as to whether they are of value as surrogate markers, whether testing intervals are adequate 
and whether such surrogate markers can be correlated with or help predict harmful endpoints.
Detection of specific ADRs as harmful properties of a medicine itself has an obvious purpose. 
These can be grouped or aggregate cases with features in common or a case series where the 
number of cases, individual causalities, inter-case consistency, and severity/seriousness can 
all be assessed. Plausibility of causal relationship between a drug and event can be discussed 
on the ground of causal assessment of each case or of a group of cases as an aggregate.
The next stage for attributing causality is to review the statistical quantification of safety data 
from individual studies. Biostatisticians can prepare and present data with tables and graphics 
as well as quantities of continuous/discrete variables. Points to consider include epidemiological 
morbidity and subjects’ background data (bias and confounders), investigational comparators, 
randomization or not, primary/secondary/surrogate endpoint, dropouts and missing data, and 
data dependency on dose and time (hazard function). All aspects of statistical testing may play a 
critical role when applying a statistical analysis plan: types of test, probability threshold (p-level), 
adjustment for multiple testing and confounders, power of test, and confident intervals.
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Toward the end of development, all data pooled through clinical trials are reviewed. This 
may require meta-analysis of individual data of clinical trials as well as meta-analysis of pub-
lished studies as well. It has been reported that no significant difference exists between meta-
analysis of published data and of individual data, and using published data is still considered 
the norm [19]. From different studies, there needs to be a pooling of numerators (e.g., number 
of affected patients) and denominators (e.g., number of patients or patient years) for ADR 
frequency estimation; frequency expression as “number needed to treat to harm,” pooling of 
within-study and between-treatment group differences.
After AE assessment, if necessary, a sponsor should update the investigator’s brochure and 
continue developing the labeling and future surveillance plan. Accordingly, Core Safety 
Information of an investigator’s brochure should be based on the Company Core Safety 
Information, which in turn will be transferred to the Summary of Product Characteristics. 
To extend development, phase IV studies are possible, for example, with registers for long-
term follow-up, observational studies for safety in clinical setting or using the large clinical 
database.
3.2. Qualitative data: case narrative
Many algorithms and classification systems on causality have been proposed; however, none 
has been agreed and accepted by everyone. In recent years, it has been questioned whether it 
is worthwhile to spend much effort conducting causality assessment on individual suspected 
ADR reports. The reason why is that ICSRs are considered relatively weaker as an evidence 
for causality than compared to the frequency of events in the actively treated group with that 
of the comparative control group. If randomized controlled trials found significant differ-
ences with appropriate statistical power, it is likely that pharmacotherapy was the cause of 
event, that is, the medicinal product directly caused the event under certain conditions of use. 
It is important to ensure robustness and objectivity of the trial is preserved by blinding (as 
qualitative assessment of unblinded data is considered subjective). But can even the best con-
duct clinical trials replace spontaneous reporting? Clinical trials from the early development 
phase to phase IV cannot replace spontaneous ADR reporting systems for detecting very rare 
ADRs, and it is not realistic to conduct a large-scale epidemiological survey/study for each 
new drug. Large databases may consider a signal such a rare ADR as noise and so it may be 
missed. Therefore, even though information technology has evolved, it remains important to 
evaluate causal relationship qualitatively on ICSRs individually, using medical inference, tak-
ing into account the widely different circumstances in which they arise ranging from clinical 
trials, registries, to spontaneous reports.
As a tool to assist qualitative evaluation, A to F ADR classes have been proposed and extended 
since the 1970s. It addresses the characteristics of how to categorize ADRs pharmacologically: 
Type A—augmented; Type B—bizarre; Type C—chronic; Type D—delayed; Type E—end of 
use; and Type F—failure of therapy [20, 21].
In addition, the DoTS classification considering dose, time, and susceptibility was also pro-
posed from the viewpoint of elements that are thought to affect how side effects become 
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manifested rather than the pathology of side effects in isolation (Table 1). [21] The authors 
recognize absorption/distribution/metabolism/elimination to be included as susceptibility 
factors and, in addition, propose to consider these factors as contributing to medication error 
(contribution of human factors and other causal and predisposing factors).
WHO-Uppsala Monitoring Center advises that evaluation of causality can be categorized into 
six stages, such as certain, probable, possible, unlikely, conditional/unclassified, and unas-
sessable/unclassifiable [22], and for that the following major four aspects are to be considered 
[23]. (1) temporal relationships: What is the temporal relationship between treatment initia-
tion and the beginning of the event? How has the event changed after discontinuing treat-
ment? (negative dechallenge) Did it recur after re-administration? (positive rechallenge) (2) 
Alternative causes: Have there been exposure factors other than complications, concomitant 
medications, or medicines that can explain the event occurrence? (3) Nature of the event: 
Some clinical events are often caused immediately by drugs (e.g., swelling in injection site). 
(4) Plausibility: Is the reaction already recognized by this medicine? (Is it a known side effect 
with this class?) Can the explanation for mechanism of event be derived from its known phar-
macological action?
As a more specific evaluation criterion, nine criteria by Hill [24] and a number of scoring 
algorithms such as that devised by Naranjo et al. [25] can be used and applied to as part of 
causality assessment. Effective use of all these causality techniques requires practical knowl-
edge about how to blend clinical, medical, and pharmacological sciences, which it means it 
is necessary to have suitably qualified persons with such knowledge actively leading and 
involved in the assessment team. Behavioral competencies for effective performance in phar-
macovigilance have been discussed elsewhere [26].
As will be described later, it is not uncommon for elucidation of the mechanism of the 
development of ADR after many years following new drug approval often linked to 
advances in in scientific technology and research. Benefit-risk assessment that involves 
scientific review should be considered as standard operational procedures with structured 
framework to achieve feasible decision-making. However, as there are no perfect causality 
criteria, we should always bear in mind and not ignore clinical significant events regard-
less of causality unless there is overwhelming evidence of other causal factors which are 
obvious.
Dose Time Susceptibility
Toxic
Collateral
Hypersusceptibility
Time independent
Time dependent (rapid, first dose, and early/intermediate/
late/delayed)
Age
Sex
Physiological variation
Exogenous factors
Disease
Table 1. DoTS classification of adverse drug reaction.
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3.3. Quantitative data: statistical approach
Statistics are widely used in the drug development as “biostatistics” to validate the efficiency 
of investigational products entity. What about the application of statistics to assess safety?
In the mid-1980s, the term “pharmacoepidemiology” was used for the first time, which often 
refers to the academic field of study, drug use and safety on a group level. As you can imagine 
from the phrase “epidemiology,” the “group of subjects” or “population” studied by pharma-
coepidemiology is a larger patient group than that of the clinical trial numbering up to tens 
of thousands or even an entire national population. This academic field has greatly expanded 
in the 1990s which is underpinned by the increased use of computerized databases including 
prescription records and clinical outcomes to investigate safety issues quickly and efficiently, 
as well as sophisticated computer technology, which enables high-enough performance to 
handle enormous amounts of data.
More recently, the design of pharmacoepidemiologic studies has turned to using big data. 
No matter the size of study subjects, the most challenging aspect of pharmacoepidemiology 
is its research design as with clinical trials. The place of “chance” that may lead statistically 
significant difference, “Bias” by systematic error, and “Confounding” as a third factor asso-
ciated with both drugs and events, all may contribute to a direct association between drugs 
and events, which should be considered when designing the research plan and considering 
their results. Studies on drug safety are often performed further in the post-marketing phase 
observationally. Because, a double-blind trial to verify whether a serious adverse event will 
occur to a patient can be ethically dubious as patients cannot be denied an approved effective 
medicine, and in order to mitigate weakness and strengthen observational studies, pharmaco-
epidemiological researches inevitably consider new designs. In this academic domain, study 
designs and statistical techniques have been evolved, such as self-controlled case series, new 
user design, etc., handling bias and confounding that are classic and common in cohort and 
case-control studies. Frequently used study designs in pharmacoepidemiology are described 
further in the regulatory guidelines and the academic proposals [27–29].
New designs seem to be developed and used mainly for retrospective observational database 
studies. For the question of interest, there is still needs to conduct a traditional epidemio-
logical study design for post-approval, phase IV study. As with the example of Brigham and 
Women’s Hospital epidemiological studies, it may be necessary to plan for a cohort study 
to assemble from the beginning of development. Recently, many large-scale databases are 
becoming available and it is prudent to first make use of them. When choosing a database, 
you should make sure that prescription records, event data, and health-related information, 
such as gender and age, are available. If you can reconcile patient ID, separate databases may 
be combined. However, this requires epidemiological knowledge and experience.
3.4. Much to do in the post-marketing phase to fully develop and define a 
medicine’s properties and potential
Based on the principle of ICH E2E, risk management plans have become a part of a new drug 
approval document to be submitted to the regulatory authorities in many countries/regions. 
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Most of the processes for evaluating ADRs are similar in the pre- and post-authorization 
phases, although differences are found in data source for evaluation which impact on the 
quality and meaning of an adverse event case. One of the significant differences is that the 
spontaneous reporting system plays a critical role in post-authorization for both qualitative 
and quantitative analysis, especially for the identification of potential safety issues as soon as 
possible. This requires the process for quality management of spontaneous reporting so that 
spontaneous reporting to be improved [30].
One of major challenges of ICSR reporting is its quality variation over time and between dif-
ferent geographical regions, depending on reporting cultures and regulations. This means it 
is to be expected that the databases of aggregated ICSRs can vary between countries/regions 
and indicate different drug-event combinations as safety signals. To illustrate these differ-
ences, a comparison study was performed on ICSRs databases between the United States 
and Japan, namely, FDA Adverse Events Reporting System (FAERS) and Japanese Adverse 
Drug Event Report (JADER) [31]. The ICSR elements and their definitions defined by ICH 
have been implemented by countries/regions. It is expected that a case should be recorded in 
the same manner in different countries, however, not in reality. In the study, although both 
databases limitedly open the data elements, there were discrepancies in the type of reported 
AEs, reported drugs, reporter type, seriousness, and average number of reported events per 
case, between the JADER and FAERS. For example, the average number of AEs per case was 
1.6 (SD = 1.3, max = 37) in the JADER and 3.3 (SD = 3.5, max = 62) for the Japanese cases in 
the FAERS; “drug exposure during pregnancy,” “no adverse events,” and non-serious cases 
are present in FAERS, but as these are not mandatory for electronic submission in Japan, few 
reports from non-professionals were found in the JADER.
These differences are mostly due to regulations and customs. In addition to these, social fac-
tors and healthcare systems also have a considerable impact. Interstitial lung disease (ILD) is 
an example of how an AE can be differently reported in Japan based on social-induced report-
ing bias. Japan has experienced serious social concerns with ILD related to several drugs and 
simultaneously, diagnosis with x-ray imaging is available in Japanese clinics and hospitals 
so it would appear that ILD could be more efficiently detected than other countries. Coding 
rules also may affect ICSRs data, because medical terminologies of ICSRs are submitted using 
codes inputted by a reporting company, where the company culture may have been embed-
ded in the process so that bias may arise. All these unresolved biases threaten internal and 
external validity of the ICSR databases.
Nevertheless, the ICSR database is still very useful for review in the post-approval phase. It 
gives an opportunity to detect any safety signal (a combination of a medicine and an event 
considered to require more detailed examination) that would require a closer scrutiny. 
Collecting individual cases in the post-approval phase is said to be particularly suited for 
capturing suspected cases of serious and rare adverse drug reactions; however, if healthcare 
professionals, especially physicians, do not report the event, the potential safety risk cannot 
be noticed. In order to complement this, those who evaluate actively post-marketing data are 
extending their activities to include looking for signals from a large amount of information, 
which is out of scope of this chapter.
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Data management and statistical methods draw attention to the need to press forward by 
improving the efficiency of data analysis. However, it is hard for database analyses to iden-
tify issues such as dependency problems of medicines such as benzodiazepines and many 
delayed side effects unless they are flagged as a safety problem by patients’ complaints in the 
first place through spontaneous reporting.
4. Remaining issues and the future for pharmacovigilance
4.1. Characteristics of phase IV studies
Phase IV studies, either interventional or observational studies, have to be appropriately 
designed, according to the purpose/hypothesis about drug efficacy, effectiveness, or safety. 
To say that “the medicine is safe” in regulatory science means that the probability of hazard 
is low and acceptable, as compared to the disease to be treated and the benefit expected 
by the drug. In that sense, the safety concerns of the marketed drug are always linked to 
the benefit of the drug which has been accepted in the approval process. Unlike “efficacy” 
review, observational studies prevail in drug safety due to ethical reasons. Clinical trials 
are designed to reduce a statistical erroneous conclusion that efficacy exists when it really 
does not (Type I error). It defines “efficacy” to be tested, and statistical analysis is planned 
on the basis of a single hypothesis of the efficacy, thus the testing of multiple hypothesis 
within a single study is discouraged. However, there are a lot of potential types of ADRs that 
would be inappropriate to examine in a randomized trial. This is another reason for using 
surveillance to catch any signs of hazard and using prospective/retrospective longitudinal 
observational studies and pharmacoepidemiological database studies to assess the occur-
rence of ADRs. In addition, population-based design is of significance to compensate limited 
generalizability in clinical trials. “Effectiveness” in real-world clinical settings of a drug is 
scrutinized normally by non-interventional study or trial where the drugs are prescribed as 
per usual based on the terms of a drug marketing license. Definition of “effectiveness” may 
be prone to chance of subjective variation of the prescribing physician, which would make 
designing a study difficult.
Some registration systems provide an overview of clinical trials and studies: purpose, study 
type, intervention, recruitment criteria, etc. One such system in regulatory use is  ClinicalTrials.
gov, where information on phase II to IV studies of drugs, biological products, and medical 
devices regulated by the FDA is submitted [32–34]. Approximately 20,000 phase IV studies, 
over a half of which were interventional, have been registered in ClinicalTrials.gov; among over 
250,000 studies in 203 countries, noticeably, registered phase IV studies include studies without 
drugs and observational studies [35, 36]. Those interventional studies examine various aspects 
of efficacy, pharmacodynamics, pharmacokinetics and other pharmacological aspects. Safety 
is often focused along with efficacy as described above, and 4392 of 4722 safety studies were 
aimed at efficacy as well as safety from 2004 to 2014. Of those which were interventional stud-
ies, 226 (68.5%) of them recruited less than 300 patients. Again, from a public health view point 
of generalizability, safety profile cannot be efficiently informed through clinical studies alone.
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4.2. Utilizing and making sense of new data sources
Real world data (RWD) refers to all the data relating to patient health status and/or the deliv-
ery of health care routinely collected from a variety of sources [37]. They are collected under 
day-to-day circumstances and not through international trials with a control or comparative 
group. This means data are outside the controlled constraints of conventional randomized 
clinical trials. Especially occurring in the post-approval setting, the data can be used to evalu-
ate what happens when a medicine is used in normal clinical practice. Such data can arise 
from a number of sources, not only in the clinical settings, but also social settings. Therefore, 
RWD can be found in electronic health records (EHRs), claims and billing activities, product 
and disease registries, patient-related activities in out-patient or in-home use settings, health-
monitoring devices and even blogs if possible [38]. In addition, RWD can include data on 
outcomes (both clinical and patient-reported), resource use (medical institutions, patient, and 
societal), treatment pathways, service models, patient preference, experience, and compli-
ance. Secondary research data derived from routinely collected data is also applicable. Real-
world evidence in drug development is, in turn, the clinical evidence regarding the usage and 
potential benefits or risks of a medical product derived from the analysis of all of this RWD.
RWD and RWE may not be the best thing for collecting efficacy data, and interventional trials 
are essential and inevitable to prove efficacy of medicinal entity. The methodology to utilize 
RWD would elaborate the better use of RWD for the monitoring of safety information in the 
post-approval phase to add further information on benefit-risk balance [39]. As of today, the 
majority of studies with RWD are safety-focused, and real-world pharmacovigilance is one of 
the main drivers currently for collection of RWD for many companies, based on post-authori-
zation requirements for safety evaluation in real-world patients. It is reported that registries, 
in the form of a cohort study, have not sufficiently enrolled participants [40], and it should 
bear in mind that any type of data source has difficulties and limitations in collection and 
quality of its data.
4.3. Necessity of pharmacovigilance for the development of pharmaceuticals
Access to new therapies in oncology has depended on the results of post-approval RWD. There 
are some drugs approved based on progression-free survival using Kaplan-Meier survival 
analysis with no difference in overall survival time. Can the data of progression-free survival 
really support a clinically meaningful effect of anticancer drugs? Would not data about the 
overall survival period be better? It may be agreed with regulators that data on the over-
all survival time derived from post-approval observational research be evaluated with the 
results fed back to healthcare professionals through updates to the package insert, etc. Such 
an approach may well lead to increase in utilization of conditional approvals.
Beginning with imatinib, the development of molecular-targeted drugs and utilization in clin-
ical practice became popular especially in the twenty-first century. However, it has been noted 
in recent years that many genetic mutations are present in the signal transduction system and 
from this scientist can more easily predict outcomes concerning effectiveness and safety. Even 
though we cannot fully clarify molecular targeted drugs at the time of approval, research 
for confirming gene mutation should continue to be recommended after marketing by using 
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companion diagnostic agents often as personalized medicine. As the tragedy of thalidomide 
was one milestone, the lessons learned after gefitinib’s marketing in Japan can be considered 
a further milestone for molecular targeted drugs. Gefitinib was the second molecular-targeted 
drug that was launched in Japan ahead of the world in July 2002 based on the approved 
indication of lung cancer. Some years later, it was confirmed that the effectiveness is valid for 
small cell lung cancer patients with EGFR gene mutation (L858R or Exon 19 deficiency), and 
that the mutation of the ATP binding site is more common in Oriental women such as Japan 
and China [41]. In terms of safety, many adverse reaction cases of Interstitial Lung Disease 
were reported at the time of clinical trials, but the mechanism of action that caused such an 
adverse reaction had not yet been elucidated.
However, there remains a huge question about the feasibility for a company being obliged to 
obtain even more data during development by investing in post-marketing safety studies 
and effectiveness studies. In recent years, regulatory authorities have streamlined reviews for 
approval, such as FDA’s Accelerated Approval Program, and there are increasing numbers of 
applications requiring post-approval safety measures at the time of approval. It is considered as 
one possible solution to replace conducting many phase IV studies and in vitro studies with uti-
lizing RWD, as described above. However, it should be noted that profiles of each database vary 
so much that they produce different results even if you study with the same objective, for exam-
ple, pioglitazone [42]. Therefore, it is necessary to sufficiently clarify the risk minimization actions 
in a RMP, and to keep these in mind when choosing a database for quantitative assessment.
5. Conclusions
Pharmacovigilance can be defined as a multidisciplinary science consisting of systematic 
activities and processes relating to the detection, assessment, understanding, and prevention 
of adverse effects or any other problems related to medical healthcare products and their 
handling throughout their lifecycle, thus mitigating risk and maximizing benefits for patients. 
These activities include those required to monitor and assess a quality system embedded in a 
just and fair culture that facilitates reporting, communication, and organizational learning to 
demonstrate that the system is performing according to guiding safety principles agreed by 
all stakeholders. What has been learned from the history of various medicines is that the bal-
ance between benefit and risk can change from time to time based on the obtained experience 
and information, and that taking multiple approaches to a certain safety research objective can 
often result in different answers. Therefore, pharmacovigilance is a challenging and evolving 
multidisciplinary science that has to be applied logically throughout drug lifecycle. This chap-
ter presented what are available in practice to assess and profile safety with a central aspect of 
adverse drug event/reaction throughout the development phase to the post-marketing phase.
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